These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 17223921

  • 1. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF, Crawford ED, Kramer BS, Andriole GL, Gelmann EP, Grubb R, Greenlee R, Gohagan JK.
    BJU Int; 2007 Apr; 99(4):775-9. PubMed ID: 17223921
    [Abstract] [Full Text] [Related]

  • 2. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK, PLCO Project Team.
    J Natl Cancer Inst; 2005 Mar 16; 97(6):433-8. PubMed ID: 15770007
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
    Gosselaar C, Roobol MJ, Roemeling S, Schröder FH.
    Eur Urol; 2008 Sep 16; 54(3):581-8. PubMed ID: 18423977
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat SF, Fisch M, Graefen M, Pummer K, Chun FK.
    BJU Int; 2012 Jun 16; 109(11):1627-35. PubMed ID: 21939492
    [Abstract] [Full Text] [Related]

  • 7. Variation in patterns of practice in diagnosing screen-detected prostate cancer.
    Nam RK, Toi A, Trachtenberg J, Jewett MA, Klotz L, Fleshner N, Bagnell PS, Sweet J, Sugar L, Narod SA.
    BJU Int; 2004 Dec 16; 94(9):1239-44. PubMed ID: 15610097
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer.
    Schoenfield L, Jones JS, Zippe CD, Reuther AM, Klein E, Zhou M, Magi-Galluzzi C.
    BJU Int; 2007 Apr 16; 99(4):770-4. PubMed ID: 17233800
    [Abstract] [Full Text] [Related]

  • 13. Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0 ng/ml or less.
    Ito K, Kubota Y, Yamamoto T, Suzuki K, Fukabori Y, Kurokawa K, Yamanaka H.
    Cancer; 2001 Feb 15; 91(4):744-51. PubMed ID: 11241242
    [Abstract] [Full Text] [Related]

  • 14. Predictors of prostate cancer on extended biopsy in patients with high-grade prostatic intraepithelial neoplasia: a multivariate analysis model.
    Abdel-Khalek M, El-Baz M, Ibrahiem el-H.
    BJU Int; 2004 Sep 15; 94(4):528-33. PubMed ID: 15329106
    [Abstract] [Full Text] [Related]

  • 15. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C.
    Clin Trials; 2010 Aug 15; 7(4):303-11. PubMed ID: 20571134
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K, Raaijmakers R, Roobol M, Wildhagen M, Yamanaka H, Schröder FH.
    Cancer; 2005 Jan 15; 103(2):242-50. PubMed ID: 15578715
    [Abstract] [Full Text] [Related]

  • 20. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
    Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M.
    BJU Int; 2008 Jan 15; 101(2):165-9. PubMed ID: 17850361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.